{"name":"Shanghai Zhimeng Biopharma, Inc.","slug":"shanghai-zhimeng-biopharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CB03-154","genericName":"CB03-154","slug":"cb03-154","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"CB03-154","genericName":"CB03-154","slug":"cb03-154","phase":"phase_2","mechanism":"CB03-154 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNYk5fUTdiZXJyZXNiS3ZQc1ZYRldqQ1BKQ2tEcVdqRlZ1U0o2dzNLSEwyU2o3czBDVnpKWC1aYnFJMVNUZ0hDZFRpS2trZGpzUGRJcXltYXoxYWdaLXhzems0VG1ObS1sRzdmUmJ1OFpnSHVwcXpCQXlvdVcxcjJOTWlVTHllcFZRWWItWGJneXI3cGdVb3lXS0RRRktkS0xYMGNqcTY2eXRWTHBTM0NrTGJvRjN6a2ctZWlKTzQyZFZMNWlTWDU1SzZINjh4bVdOVkUxMHhhSjAzX2QxZWMxUDM3MUxSbXVmdkJ2aFhZWGRKbU5IR19kVTN2WVJOSTZkOHpRWWdoVnFFTnNhaGc?oc=5","date":"2026-04-07","type":"trial","source":"Barchart.com","summary":"Hepatitis B Virus Infection Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com","headline":"Hepatitis B Virus Infection Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Trea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPWUdSZi1GbGcxVF9ZSUVRWEdMSVNBbzFDTDdfb0hCSkNKelY3ZmFkV0JWQzRSaXBPelRLVzNXSFlQVHE5NW1zdHk0dENmR2x3bWMyc0RkSFAwRzA1ZEM3Tmp6NG5fbWRucl9xbnFPUWUzX3dPTlBPZ0lobkFsRVM5azNQTURCY0gtZFBnWHQyT3pBUVc0alF1X2U1cVE4Sl9nc01fNVNnTlBCSVBmck9rdzQtR0hsS0hXbUVWaEk3MV8tOW8zQVZIMlk3bUp4U2VlT1hsT2V0dkJKRE1qQkE?oc=5","date":"2025-11-03","type":"trial","source":"BioPharma APAC","summary":"Shanghai Zhimeng Biopharma Begins Phase 2/3 Trial of Next-Generation Potassium Channel Opener for ALS - BioPharma APAC","headline":"Shanghai Zhimeng Biopharma Begins Phase 2/3 Trial of Next-Generation Potassium Channel Opener for ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOQ0RlU0RtWDVhbW4xVGhOWjhJX0NvMHE5N0JpbU04RGJTZ1VoRDVnM1Q5Wmo0NFlzUFNVZVFiRTY1dG9VNWNQX2NGZnVhUVBPV2NGbjNkYWhrMEVFcU1mTzFPYnQzSjJWOUJVNG9xdFNTVjloWFo4RWxMaXVSc3luVVB2WS1lcHVtWVUtQ1EwQVI4WXh5VzJ2NHdPWURGTndzYnlhNUJkZ1YyX0p3RWliV21zSkh3TTVFNmVKcW9PTjZMb3lBYlhEZURpNkRPcm5TWTRtdFNJcWQ?oc=5","date":"2025-09-12","type":"trial","source":"BioPharma APAC","summary":"Zhimeng Biopharma Secures China’s Green Light for Phase 2 Trial of Next-Gen Epilepsy Drug CB03-154 - BioPharma APAC","headline":"Zhimeng Biopharma Secures China’s Green Light for Phase 2 Trial of Next-Gen Epilepsy Drug CB03-154","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQVHo5ZkpkZHdDeUdWZldhN1Z2eGE4OF9xOHJyWVhRdlpETTVIemZCU1g5SmRWdjBQOVMwN1JrWVJLSE9xdmd1ekxrclY1VWFpTnVSMHFFRHZrZUxreGVuR2h6T21YRW1WdWI5OFViVlA0MkZ2ajhUQmVSVTRHblV2RUpoRzVoc1VIY2loQ01UM3RLSFp5WlJYNU1hc3pYM3Z0UW51QUdsbThEQ1hFSV9QVHctMjctTGtpYkNReHRKSHRlV04tRmxteQ?oc=5","date":"2024-12-13","type":"earnings","source":"BioWorld News","summary":"CB-03 selectively activates KCNQ2/3 channels and prevents seizures in models of epilepsy - BioWorld News","headline":"CB-03 selectively activates KCNQ2/3 channels and prevents seizures in models of epilepsy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQM0ItVjUtSHF5dHRxLUFEUFM5YmFsYnRST0hvOTBWQ0tiRGQ4cHg5LW1MWUEzaUFvOTMwQ0ZSLUVaM19wVFp2QUtHVmFMQmxpUUk5a29QSnJMYTJUX0RQd3c0cERjYVMwdlhKNzJmdHNScHYtUmVKOXA0ZFV4N2l2cW9vZnZSVXE5MmJnMkxuVWpkTkZ4U1I4RXY1Q1ExcTd4ZDl3TEE1QTduUEx3QnlRQkcyZEVIY2t5M1hDTVBqLTc3UHlTSG55RU52VklJT2pLcWl5QzhkV3EzZw?oc=5","date":"2022-04-01","type":"trial","source":"BioPharma APAC","summary":"Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase -- Clinical Trial of CB06 - BioPharma APAC","headline":"Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase -- Clinical Trial of CB06","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOYVhlNHloQ3RobXU4bDNVZFVWYk8zVkt1QTY2OUcxdmNsdmpKdjNnc2NVLXUwSHZJb3VPc1BZTGVLczUxYWNwLTF6SzJ0cVNETEdIYVgwM3RKaXNhbVF6cFJjRURseXRzVlBFbjFYc0hyRGQ5dS1QY29oR1Y1ZzJkQWw4RVJzeXQxRUdrbEdtb2hQMWstYnhtR2pCUGc?oc=5","date":"2020-03-05","type":"trial","source":"NAI500","summary":"Shanghai Zhimeng Starts US Phase I Trial of Novel HBV Treatment - NAI500","headline":"Shanghai Zhimeng Starts US Phase I Trial of Novel HBV Treatment - NAI500","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}